DWA
SEEL

Dorsey Wright & Associates’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Dorsey Wright & Associates’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3
Closed -$51.8K – 367
2021
Q1 		$51.8K Buy
+3
New +$35K 0.61% 43

Other funds holding SEEL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Dorsey Wright & Associates's SEEL Position: Q2 2021 in Review

Dorsey Wright & Associates sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q2 2021, closing a stake of 3 shares — an estimated $51.8K sold.

Dorsey Wright & Associates first reported a position in SEEL in Q1 2021 and held it in 1 quarter. The position peaked at $51.8K in Q1 2021. 92 funds tracked by Wall St. Rank hold SEEL as of Q2 2021.

  • Dorsey Wright & Associates reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Dorsey Wright & Associates sold 3 Seelos Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $51.8K.
  • Dorsey Wright & Associates first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Dorsey Wright & Associates's Seelos Therapeutics, Inc. Common Stock position peaked at $51.8K in Q1 2021.
  • 92 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Dorsey Wright & Associates's 13F filing for Q2 2021, filed 23 Jul 2021.